Published in Oncologist on August 26, 2010
Sexual problems, communication patterns, and depressive symptoms in couples coping with metastatic breast cancer. Psychooncology (2012) 0.83
Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. Curr Oncol (2013) 0.82
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) (2011) 0.79
Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. BMJ Open (2014) 0.75
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol (2013) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol (1997) 7.79
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
Skeletal complications of malignancy. Cancer (1997) 5.41
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol (2009) 4.69
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev (2008) 3.13
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature (2008) 2.51
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol (2004) 2.14
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol (2003) 1.72
Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res (2004) 1.14
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer (2008) 1.04
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat (2009) 0.93
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol (2009) 4.69
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Adherence with colorectal cancer screening guidelines: a review. Prev Med (2004) 2.87
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin (2005) 2.57
The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol (2013) 2.41
Use of colonoscopy for colorectal cancer screening: evidence from the 2000 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2005) 2.17
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol (2009) 1.99
The effect of depression on health care utilization and costs in patients with type 2 diabetes. Manag Care Interface (2006) 1.56
Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population. Clin Ther (2005) 1.41
Real-time functional magnetic resonance imaging neurofeedback for treatment of Parkinson's disease. J Neurosci (2011) 1.40
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist (2010) 1.37
Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat (2007) 1.30
Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother (2006) 1.18
Determinants of adult influenza and pneumonia immunization rates. J Am Pharm Assoc (2003) (2003) 1.16
Task-irrelevant visual motion and flicker attenuate the attentional blink. Psychon Bull Rev (2006) 1.12
Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol (2005) 1.11
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin (2007) 1.08
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer (2008) 1.02
Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg (2012) 1.02
Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm (2008) 1.01
Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes (2006) 0.97
Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis. Clin Ther (2006) 0.95
Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis (2010) 0.95
Changes in weight and co-morbidities among adolescents undergoing bariatric surgery: 1-year results from the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis (2012) 0.94
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat (2009) 0.93
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids (2011) 0.93
Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat (2007) 0.93
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res (2013) 0.92
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett (2011) 0.87
Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med (2011) 0.87
Enhancing the net benefits of disseminating efficacious prevention programs: a note on target efficiency with illustrative examples. Adm Policy Ment Health (2008) 0.86
Targeting endocrine resistance: is there a role for mTOR inhibition? Clin Breast Cancer (2010) 0.86
Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires*. Curr Med Res Opin (2008) 0.86
Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo. Int J Cancer (2002) 0.85
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast Cancer Res Treat (2013) 0.84
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. Am J Health Syst Pharm (2011) 0.84
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Health Econ (2011) 0.83
Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol (2011) 0.82
An improved experimental model for understanding the impact of sperm DNA fragmentation on human pregnancy following ICSI. Reprod Sci (2012) 0.81
Microarray technology displays the complexities of the humoral immune response. Expert Rev Mol Diagn (2011) 0.81
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin (2011) 0.80
Time trends in the outcome of elderly patients with breast cancer. Breast J (2008) 0.80
Assessing predictors of influenza and pneumonia vaccination in rural senior adults. J Health Soc Policy (2003) 0.80
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin (2010) 0.79
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Curr Med Res Opin (2012) 0.79
Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Hosp Pract (1995) (2015) 0.78
Factors determining outcome after third line chemotherapy for metastatic breast cancer. Breast (2007) 0.78
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada. Pharmacoeconomics (2015) 0.78
Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients. Hosp Pract (1995) (2011) 0.78
Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Res (2015) 0.78
Identification of small-molecule inhibitors of Trypansoma cruzi replication. Bioorg Med Chem Lett (2011) 0.78
Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. Gend Med (2008) 0.77
Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. Curr Drug Saf (2014) 0.76
Effect of ethnicity on weight loss among adolescents 1 year after bariatric surgery. World J Diabetes (2013) 0.75
Mapping eye movements in 3D: Preferential fixation of surface curvature minima during object recognition in stereo viewing. J Vis (2015) 0.75
Breast cancer (non-metastatic). Clin Evid (2004) 0.75
Breast cancer (non-metastatic). Clin Evid (2003) 0.75
Outcomes of inappropriate prescribing of beta-blockers after an acute myocardial infarction in a Medicaid population. Ann Pharmacother (2005) 0.75
Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. Melanoma Res (2014) 0.75
Target Detection in Visual Search: Unravelling the Pupillary Response. J Vis (2015) 0.75
Assessing predictors of influenza and pneumonia vaccination in rural senior adults. J Health Soc Policy (2004) 0.75
New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France. IDrugs (2004) 0.75
Breast cancer: non-metastatic. Clin Evid (2002) 0.75
The effect of group size on vigilance in a semi-solitary, fossorial marsupial (Lasiorhinus latifrons). Behav Processes (2013) 0.75
Breast cancer: non-metastatic. Clin Evid (2002) 0.75
Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry (2015) 0.75